US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
IceCure Medical Ltd (ICCM)
IceCure Medical Ltd (ICCM) ニュース

ICCM

IceCure Medical (ICCM)

IceCure Medical Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ICCM

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/04	21 : 50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/06/04	21 : 30	PR Newswire (US)	FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/28	21 : 45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/28	21 : 30	PR Newswire (US)	IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/28	20 : 31	IH Market News	U.S. Futures Present Mixed Pre-Market Performance, Oil Prices Surge	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/22	05 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/21	21 : 30	PR Newswire (US)	IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/20	21 : 30	PR Newswire (US)	IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/07	21 : 40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/05/07	21 : 30	PR Newswire (US)	Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	NASDAQ:ICCM	IceCure Medical Ltd
2024/04/15	21 : 35	PR Newswire (US)	IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer	NASDAQ:ICCM	IceCure Medical Ltd
2024/04/03	21 : 30	PR Newswire (US)	IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance	NASDAQ:ICCM	IceCure Medical Ltd
2024/04/03	20 : 11	IH Market News	U.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge Higher	NASDAQ:ICCM	IceCure Medical Ltd
2024/04/02	21 : 30	PR Newswire (US)	IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	NASDAQ:ICCM	IceCure Medical Ltd
2024/03/27	21 : 30	PR Newswire (US)	IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	NASDAQ:ICCM	IceCure Medical Ltd
2024/03/19	21 : 30	PR Newswire (US)	IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	NASDAQ:ICCM	IceCure Medical Ltd
2024/03/12	21 : 30	PR Newswire (US)	IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes	NASDAQ:ICCM	IceCure Medical Ltd
2024/03/07	22 : 30	PR Newswire (US)	IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference	NASDAQ:ICCM	IceCure Medical Ltd
2024/03/04	22 : 35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/03/04	22 : 30	PR Newswire (US)	IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024	NASDAQ:ICCM	IceCure Medical Ltd
2024/02/27	22 : 00	PR Newswire (US)	Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop	NASDAQ:ICCM	IceCure Medical Ltd
2024/02/26	22 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/02/26	22 : 00	PR Newswire (US)	Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer	NASDAQ:ICCM	IceCure Medical Ltd
2024/02/15	22 : 00	PR Newswire (US)	IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan	NASDAQ:ICCM	IceCure Medical Ltd
2024/01/30	22 : 15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/01/30	22 : 00	PR Newswire (US)	U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer	NASDAQ:ICCM	IceCure Medical Ltd
2024/01/29	22 : 00	PR Newswire (US)	IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class	NASDAQ:ICCM	IceCure Medical Ltd
2024/01/16	22 : 00	PR Newswire (US)	IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation	NASDAQ:ICCM	IceCure Medical Ltd
2024/01/13	06 : 39	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ICCM	IceCure Medical Ltd
2024/01/13	06 : 18	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd

Showing the most relevant articles for your search:NASDAQ:ICCM

1 2 3 4 5 6 次へ >>

NLBNPIT1ZFW1 20241220 35

NLBNPIT1RYG2 20240621 14

Intesa Sanpaolo

Leonteq Securities

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約